최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기International journal of antimicrobial agents, v.16 no.4, 2000년, pp.501 - 505
Novelli, A. (Corresponding author: Tel.: +39-055-4271 ext. 310) , Fallani, S. (fax: +39-055-4271 ext. 280) , Cassetta, M.I. (Dipartimento di Farmacologia Preclinica e Clinica, Università) , Conti., S. (degli Studi, Viale Pieraccini, 6–)
초록이 없습니다.
Diagn. Microbiol. Infect. Dis. Craig 22 89 1995 10.1016/0732-8893(95)00053-D Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins
Clin. Infect. Dis. Craig 26 1 1998 10.1086/516284 Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men
DICP Ann. Pharmacother. Zhanel 25 153 1991 The postantibiotic effect: a review of in vitro and in vivo data
Scand. J. Infect. Dis. Suppl. Hanberger 74 118 1990 Pharmacodynamics of beta-lactam antibiotics on Gram-negative bacteria: initial killing, morphology and postantibiotic effect
Eur. J. Clin. Microbiol. Infect. Dis. Hanberger 10 927 1991 10.1007/BF02005446 Post-antibiotic effect of beta-lactam antibiotics on gram-negative bacteria in relation to morphology, initial killing and MIC
Craig 403 1991 Antibiotics in Laboratory Medicine Postantibiotic effect
Antimicrob. Agents Chemother. Libby 42 78 1998 10.1128/AAC.42.1.78 Postantibiotic effect in Escherichia coli determined with real-time metabolic monitoring
Antimicrob. Agents Chemother. Odenholt 41 2522 1997 10.1128/AAC.41.11.2522 Studies of the killing kinetics of benzylpenicillin, cefuroxime, azithromycin, and sparfloxacin on bacteria in the postantibiotic phase
Farmaci & Terapia Novelli 14 1 1997 Effetto post-antibiotico in vitro di β-lattamine orali
Periti 1988 Attualita delle cefalosporine in chemioterapia
Mayo Clin. Proc. Marshall 74 187 1999 10.4065/74.2.187 The cephalosporins
Le infezioni in Medicina Russo 4 Suppl. 1 3 1996 Aspetti microbiologici e farmacologici clinici del cefacloro e di una nuova preparazione farmaceutica: il cefacloro a rilascio modificato
Drugs Perry 52 125 1996 10.2165/00003495-199652010-00009 Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy
Drugs Wiseman 45 295 1993 10.2165/00003495-199345020-00008 Cefprozil. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential
Drugs Lode 47 Suppl. 3 10 1994 10.2165/00003495-199400473-00004 Comparative pharmacokinetics of the new oral cephalosporins
Clin. Pharmacokinet. Klepser 28 5 361 1995 10.2165/00003088-199528050-00003 Clinical pharmacokinetics of newer cephalosporins
Drugs Bryson 45 589 1993 10.2165/00003495-199345040-00009 Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use
Drugs Frampton 44 889 1992 10.2165/00003495-199244050-00011 Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential
Drugs Markham 49 1007 1995 10.2165/00003495-199549060-00010 Cefixime. A review of its therapeutic efficacy in lower respiratory tract infections
Scand. J. Infect. Dis. Suppl. Eden 39 48 1983 Penetration of cefaclor to adenoid tissue and middle ear fluid in secretory otitis media
Int. J. Clin. Pharmacol. Res. Jetlund 11 1 1 1991 Comparison of the serum and tissue concentrations of cefuroxime from cefuroxime axetil and phenoxymethylpenicillin in patients undergoing tonsillectomy
Clin. Pharmacokinet. Blouin 25 172 1993 10.2165/00003088-199325030-00002 Cefetamet pivoxil clinical pharmacokinetics
Eur. J. Clin. Microbiol. Infect. Dis. Scaglione 15 940 1996 10.1007/BF01690513 Ceftibuten concentrations in human tonsillar tissue
Pathol. Biol. (Paris) Begue 37 433 1989 Tonsil diffusion of cefixime in children
Antimicrob. Agents Chemother. Shyu 37 1180 1993 10.1128/AAC.37.5.1180 Penetration of cefprozil into tonsillar and adenoidal tissues
Antimicrob. Agents Chemother. Shyu 38 2210 1994 10.1128/AAC.38.9.2210 Penetration of cefprozil into middle ear fluid of patients with otitis media
Acta Otolaryngol. Suppl. (Stockh.) Ernstson 424 7 1985 10.3109/00016488509121604 Penetration of cefaclor to adenoid tissue and middle ear effusion in chronic OME
Pediatr. Infect. Dis. J. Haddad 10 294 1991 10.1097/00006454-199104000-00006 Concentration of cefuroxime in serum and middle ear effusion after single dose treatment with cefuroxime axetil
Antimicrob. Agents Chemother. Nix 35 1947 1991 10.1128/AAC.35.10.1947 Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning
Ann. Ital. Med. Int. Mazzei 7 Suppl. 3 67 1992 Concentrazioni plasmatiche e tissutali degli antibiotici: qual e il loro valore predittivo?
Antimicrob. Agents Chemother. Barry 38 2419 1994 10.1128/AAC.38.10.2419 In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993
Antimicrob. Agents Chemother. Jacobs 43 1901 1999 10.1128/AAC.43.8.1901 Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study
Antimicrob. Agents Chemother. Nash 35 192 1991 10.1128/AAC.35.1.192 Comparison of the activity of cefixime and activities of other oral antibiotics against adult clinical isolates of Moraxella (Branhamella) catarrhalis containing BRO-1 and BRO-2 and Haemophilus influenzae
GIMMOC Nicoletti 3 25 1999 Speciale A. Osservatorio epdiemiologico italiano. Patogeni batterici respiratori comunitari e nosocomiali:analisi delle resistenze nel 1997. Haemophilus influenzae, Haemophilus parainfluenzae e Moraxella catarrhalis
GIMMOC Schito 3 11 1999 Osservatorio epidemiologico italiano. Patogeni batterici respiratori comunitari e nosocomiali:analisi delle resistenze nel 1997. Streptococcus pneumoniae
J. Antimicrob. Chemother. Spangler 31 273 1993 10.1093/jac/31.2.273 Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829
Antimicrob. Agents Chemother. Fung-Tomc 39 533 1995 10.1128/AAC.39.2.533 Antibacterial activities of cefprozil compared with those of 13 oral cephems and 3 macrolides
Antimicrob. Agents Chemother. Fitoussi 39 2560 1995 10.1128/AAC.39.11.2560 Killing activity of cefpirome against penicillin-resistant Streptococcus pneumoniae isolates from patients with meningitis in a pharmacodynamic model simulating the cerebrospinal fluid concentration profile
Antimicrob. Agents Chemother. Manduru 41 2053 1997 10.1128/AAC.41.9.2053 In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients
Antimicrob. Agents Chemother. Cappelletty 40 1148 1996 10.1128/AAC.40.5.1148 Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection model
Antimicrob. Agents Chemother. Powell 35 2042 1991 10.1128/AAC.35.10.2042 Pharmacokinetics of cefuroxime axetil suspension in infants and children
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.